DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, multicentre, open-label, dose-escalation study to determine a recommended
clinical dose (RCD) of DT-9081, followed by an expansion study of DT-9081 at RCD in
participants with advanced, recurrent or metastatic solid tumours